Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies
Ikarovec is developing novel gene therapies to treat serious, but common eye diseases
06-Jun-2023 -
Rentschler Biopharma SE and Ikarovec, which is developing novel multicistronic gene therapies to treat major ophthalmic indications, announced that the two companies have entered into a collaboration. Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the ...
adeno-associated virus
age-related macular degeneration
atrophy
+4